EA200300193A1 - SOLID DRUG FORM OF SILIMARIN AND METHOD FOR ITS OBTAINING - Google Patents

SOLID DRUG FORM OF SILIMARIN AND METHOD FOR ITS OBTAINING

Info

Publication number
EA200300193A1
EA200300193A1 EA200300193A EA200300193A EA200300193A1 EA 200300193 A1 EA200300193 A1 EA 200300193A1 EA 200300193 A EA200300193 A EA 200300193A EA 200300193 A EA200300193 A EA 200300193A EA 200300193 A1 EA200300193 A1 EA 200300193A1
Authority
EA
Eurasian Patent Office
Prior art keywords
silimarin
obtaining
solid drug
drug form
dosage form
Prior art date
Application number
EA200300193A
Other languages
Russian (ru)
Other versions
EA006157B1 (en
Inventor
Бисер Христов Кытовски
Виолета Андреева Павлова
Димитр Георгиев Атанасов
Снежана Иванова Славкова
Веселин Евгениев Даскалов
Ангел Радославов Тимчев
Тихомир Георгиев Иванов
Original Assignee
Софарма Ад
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Софарма Ад filed Critical Софарма Ад
Publication of EA200300193A1 publication Critical patent/EA200300193A1/en
Publication of EA006157B1 publication Critical patent/EA006157B1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к лекарственной форме силимарина и способу ее получения. Состав лекарственной формы и способ ее получения в соответствии с изобретением приводят к достижению высокой стабильности в условиях хранения, высоких показателей влаго- и термостойкости. Время распада - не более 30 мин, степень растворимости - менее 80% в течение 45 мин в течение всего периода хранения.The invention relates to the dosage form of silymarin and how to obtain it. The composition of the dosage form and its preparation in accordance with the invention leads to the achievement of high stability in storage conditions, high levels of moisture and heat resistance. The disintegration time is not more than 30 minutes, the degree of solubility is less than 80% within 45 minutes during the entire storage period.

EA200300193A 2002-07-05 2003-02-26 Medicamentous form of silimarin and method for its preparation EA006157B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG106909A BG65538B1 (en) 2002-07-05 2002-07-05 Medicamentous form of silimarin and method for its preparation

Publications (2)

Publication Number Publication Date
EA200300193A1 true EA200300193A1 (en) 2004-02-26
EA006157B1 EA006157B1 (en) 2005-10-27

Family

ID=31954402

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300193A EA006157B1 (en) 2002-07-05 2003-02-26 Medicamentous form of silimarin and method for its preparation

Country Status (3)

Country Link
BG (1) BG65538B1 (en)
EA (1) EA006157B1 (en)
UA (1) UA73367C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG43202A1 (en) * 1986-10-08 1988-05-16 Sasha R Mikhajjlova Solid oral therapeutic form containing silimarin

Also Published As

Publication number Publication date
BG65538B1 (en) 2008-11-28
EA006157B1 (en) 2005-10-27
UA73367C2 (en) 2005-07-15
BG106909A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
CN110124178B (en) Agilawood incense stick with effects of calming nerves and helping sleep and preparation method and application thereof
MY139730A (en) Cyclic protein tyrosine kinase inhibitors
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
EA200400357A1 (en) Disintegrating in the mouth cavity of the composition of valdecoxib
RU2009138327A (en) COMPOSITIONS AND METHODS OF DIRECTED ELIMINATION OF MUTATIONAL USE IN DIRECTED CARE THERAPY
ATE318812T1 (en) THIAZOLYL INHIBITORS OF TYROSINE KINASES OF THE TEC FAMILY
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE365733T1 (en) COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS
CY1110407T1 (en) COMPOSITION FOR ADMINISTRATION OF IRON FOR THE TREATMENT OF SPASMUSIC SCENE SYNDROME
BR0010185A (en) Compositions for food preparation
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
TW200501947A (en) Stabilized pharmaceutical composition comprising an amorphous active substance
EA200500782A1 (en) TREATMENT OF HEMORRHAGIC SHOCK
ATE350377T1 (en) SUBSTITUTED 3-PYRROLIDINE INDOLE DERIVATIVES
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
DK1635792T3 (en) Stable pharmaceutical compositions of 2-aza-bicyclo-3.3.0-octane-3-carboxylic acid derivatives
TNSN06024A1 (en) Stable modifications of tegaserod hydrogen maleate
DE50207740D1 (en) USE OF PHOSPHATIDYLSERINE FOR TREATING ATTENTION DEFICIT SYNDROME (ADHD)
EA200700979A1 (en) ORAL SOLID MEDICINE FORMS CONTAINING LOW DOSE OF ESTRADIOL
EA200300193A1 (en) SOLID DRUG FORM OF SILIMARIN AND METHOD FOR ITS OBTAINING
HUP0302748A2 (en) Fungicidal composition comprising in particular an oil of vegetable origin with high drying power
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease